Six decades of potent chemistry
Founded in 1968 in Gropello Cairoli, Italy, Farmabios has focused on the development and manufacture of highly potent small molecules from the outset. This has created institutional expertise spanning process design, analytical methods, occupational exposure management and regulatory demands.
The site infrastructure spans the full scale of HPAPI manufacture. The dedicated cGMP HPAPI capacity operates at OEB 5 with an OEL below 10 ng / m 3 and supports batch sizes ranging from a few grams in early development through to commercial-scale supply.
Containment is applied as a design standard. Isolatorbased handling covers all critical steps. Air management for HPAPI areas operates independently and the monitoring and cleaning verification procedure is built around the OEL of each compound handled rather than generic facility standards.
GMP micronisation under full OEB 5 containment extends contained processing to particle-size reduction steps, which is critical for HPAPIs where sub-micron particle engineering is a clinical or formulation requirement. The site holds EMA and FDA manufacturing approval, alongside ISO certifications across quality, safety, environmental and energy management. regulatory timelines have already been committed. Reagents that are acceptable at gram quantities may present unacceptable inhalation or skin-contact risks at kilogram scale; intermediates classified at lower OEB levels in the laboratory may exceed Band 4 thresholds when handled in bulk.
Identifying these issues after the route has been locked and regulatory documentation has been initiated is far more costly than addressing them during development. Route assessment conducted with containment implications in mind from the outset, evaluating each intermediate and reagent against its likely scale and handling conditions, is a straightforward preventive measure, but it requires manufacturing knowledge to be present in the development conversation from Day One.
The second is solid-state design. The physical characteristics of the final crystalline API— particle size, morphology and surface area— determine its dustiness and its behaviour during isolation, drying and transfer. A compound that produces fine, poorly flowing particles at the crystallisation conditions optimal for yield may require a significantly more complex containment approach than one engineered towards a coarser, denser form.
Solid-state choices made during development therefore have a direct bearing on the classification and cost of downstream manufacture, and integrating particle engineering with process chemistry from the earliest stages of development is a practical lever for managing this.
The third is analytical readiness. ICH Q3A sets threshold requirements for the identification and qualification of impurities in new drug substances that apply from the first regulatory submission onward. 5
HPAPI impurity profiles are often complex, and the analytical methods required to characterise them must be both sensitive enough to meet regulatory thresholds and robust
Inside Farmabios’ s HPAPI facility
enough to survive the transition from development laboratory to production environment. Projects that reach cGMP manufacture without validated analytical methods in place face delays that are predictable and avoidable.
Axplora is addressing these demands via a $ 60 million, 4,500 m 2 hub at Farmabios that integrates R & D, quality control and microbiology functions within a single building- a strategic expansion designed to work in close synergy with the already operational HPAPI facility. The current phase is scheduled for completion by early 2027.
It is designed explicitly to close the gap between scientific development and operational execution. By colocating analytical, development and quality functions alongside the production environment, hand-offs between phases are shortened and there is faster campaign initiation, more responsive process characterisation and tighter feedback between development data and manufacturing decisions.
The horizon
The next decade of HPAPI development will be shaped by two convergent pressures. The first is the continued expansion of ultrapotent compound classes whose
16 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981